Figure 7.
Dose-dependent inhibition of the MBL complement activation by the test compounds. Different concentrations of nafamostat (a) along with furamidine and ceritinib (b) were added in normal human serum and tested in the Wieslab ELISA kit for the MBL complement pathway activation. The IC50 values, corresponding to the compound concentrations that inhibit by 50% the MBL pathway activation, are reported for all the three compounds. Data shown represent the means ± SD of the experiments performed in duplicate.